A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
van Kesteren C, Mathĵt RA, López-Lázaro L, Cvitkovic E, Taamma A, Jimeno JM, Guzman C, Schellens JH, Misset JL, Brain E, Hillebrand MJ, Rosing H, Beijnen JH.
van Kesteren C, et al. Among authors: mathjt ra.
Cancer Chemother Pharmacol. 2001 Dec;48(6):459-66. doi: 10.1007/s002800100368.
Cancer Chemother Pharmacol. 2001.
PMID: 11800026